Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Vaccine Therapy in Treating Patients With Metastatic Melanoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Vaccine Therapy in Treating Patients With Metastatic Melanoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Vaccine Therapy in Treating Patients With Metastatic Melanoma Clinical research trials and Vaccine Therapy in Treating Patients With Metastatic Melanoma health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Vaccine Therapy in Treating Patients With Metastatic Melanoma. Vaccine Therapy in Treating Patients With Metastatic Melanoma Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Vaccine Therapy in Treating Patients With Metastatic Melanoma clinical trial. Human subjects often get the best healthcare possible for their Vaccine Therapy in Treating Patients With Metastatic Melanoma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "V" Clinical Trials Conditions > Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma



Vaccine Therapy in Treating Patients With Metastatic Melanoma

For Condition: Stage 4 Melanoma,Recurrent Melanoma,stage 3 melanoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Kimmel Cancer Center (KCC)
Synopsis: RATIONALE: Vaccines may make the body build an immune response to and kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.
Details: OBJECTIVES: I. Determine the toxicity of intralesional immunotherapy with a recombinant vaccinia virus encoding the gene for sargramostim (GM-CSF) in patients with metastatic melanoma. II. Determine the efficiency of viral infection and GM-CSF gene insertion and function in these patients. III. Determine the capacity of this regimen to generate antiviral and antitumor immunity in these patients. IV. Determine the frequency of regression of injected and uninjected lesions in these patients. PROTOCOL OUTLINE: This is a dose escalation study of intralesional recombinant vaccinia virus encoding the gene for sargramostim (GM-CSF) (recombinant vaccinia/GM-CSF vaccine). Patients are stratified by center. Patients receive small pox (vaccinia) vaccine via multipuncture technique on day 0. On day 4, patients with a major reaction in progress to the initial vaccination receive recombinant vaccinia/GM-CSF vaccine intralesionally twice weekly for 5 weeks. Only 1 lesion is treated and at least 1 measurable lesion is left untreated in each patient. Intrapatient dose escalation occurs each week. Patients with responding disease after week 5 are retreated at a clinically appropriate dose and schedule. Cohorts of 5 patients receive escalating doses of intralesional recombinant vaccinia/GM-CSF vaccine until the maximum tolerated dose (MTD) is determined. Additional patients receive vaccine at the MTD. PROJECTED ACCRUAL: Approximately 15 patients will be accrued for phase I and a total of 15 patients will be accrued for phase II of the study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven melanoma that is considered surgically incurable - Dermal, subcutaneous, or lymph node metastases required; At least 3 lesions evaluable and accessible for injection and biopsy; One lesion at least 10 mm in diameter --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: At least 8 weeks since prior chemotherapy - Endocrine therapy: No concurrent or imminent steroid therapy - Radiotherapy: At least 8 weeks since prior radiotherapy - Surgery: At least 4 weeks since prior surgery --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-1 - Life expectancy: At least 6 months - Hematopoietic: Not specified - Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN); SGOT no greater than 3 times ULN; Alkaline phosphatase no greater than 3 times ULN - Renal: Creatinine no greater than 3 times ULN - Immunologic: Clinical evidence of immune response required within 4 days of smallpox vaccination; At least 1 positive cutaneous delayed-type hypersensitivity response to 1 of the following: Microbial recall antigens; Dinitrofluorobenzene after sensitization; Purified protein derivative of tuberculin following BCG vaccination; No altered immunocompetence (e.g., immune deficiency disease or immunosuppressive therapy) in patient or household contacts; No allergy to any of the following: Polymyxin B sulfate; Streptomycin sulfate; Chlortetracycline hydrochloride; Neomycin sulfate; No history of eczema or other exfoliative skin condition in patient or household contacts; HIV negative - Other: No leukemia or lymphoma; No other malignancy within the past 3 years except superficial squamous cell or basal cell skin cancer or carcinoma in situ of the cervix or prostate; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
MichaelMastrangelo,  Study Chair,  Kimmel Cancer Center (KCC)

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia,  Pennsylvania,  19107-5541
United States
 


Additional Information:
Study ID Numbers:  CDR0000064975;  JMC-94-0843,NCI-H96-0965
Study Start Date: April 1996
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002817

Other Stage 4 Melanoma Studies:
1. Biological Therapy in Treating Patients With Metastatic Melanoma

2. Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

3. Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

4. Interferon alfa and Thalidomide in Treating Patients With Stage IV Melanoma

5. Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Related Studies:

Other Stage 4 Melanoma Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma
Modify your Search

  Other Stage 4 Melanoma Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Philadelphia Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103